Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014

      - Net revenues up 15% compared to 2013

      - Adjusted Earnings of $6.3 million, or $0.35 per share


      News provided by

      Cumberland Pharmaceuticals Inc.

      Mar 03, 2015, 04:05 ET

      Share this article

      Share this article


      NASHVILLE, Tenn., March 3, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2014 financial results. The Company's revenue grew 15% in 2014 to $37 million, resulting in Adjusted Earnings of $6.3 million or $0.35 per diluted share. At the end of 2014, Cumberland had total assets of over $95 million including $55 million in cash and investments, with no debt.

      2014 Highlights:

      Continue Reading
      Cumberland Pharmaceuticals Logo
      Cumberland Pharmaceuticals Logo

      • Continued diversification of the revenue stream through the additions of Vaprisol® and Omeclamox®-Pak to the portfolio and launch of active promotion for both brands.
      • Experienced accelerated growth from Kristalose®, which became Cumberland's largest product, through implementation of new marketing strategies.
      • Completed significant Phase IV clinical work for Caldolor®, including pediatric pain and fever studies.
      • Secured and listed four new patents, two each for Acetadote® and Caldolor® respectively, further expanding Cumberland's intellectual property position for these two brands.
      • Secured a new senior credit facility for up to $20 million with SunTrust Bank. 
      • Arranged $2 million in new funding for research activities at Cumberland Emerging Technologies (CET).

      "Cumberland rebounded strongly during 2014 returning to growth and profitability," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "Our strategy is to maximize the full potential of our commercial brands while pursuing opportunities to further expand our portfolio through acquisitions and internal pipeline advancements. We remain focused on our mission of advancing patient care through the delivery of high quality pharmaceutical products."

      Financial Results:

      Net Revenue:  For the year ended December 31, 2014, net revenues were $36.9 million, compared with $32.0 million for 2013. Net revenues were $14.9 million for Kristalose®, $11.9 million for Acetadote® including $5.8 million from our Authorized Generic, $4.1 million for Omeclamox®-Pak, $3.0 million for Vaprisol®, and $2.7 million for Caldolor®.

      For the three months ended December 31, 2014, net revenues were $9.3 million, up from $8.2 million for the prior year period.  Net revenues were $4.0 million for Kristalose®, $2.9 million for Acetadote® including $1.3 million from our Authorized Generic, $1.0 million for Vaprisol®, $0.8 million for Caldolor®, and $0.6 million for Omeclamox®-Pak.

      Operating Expenses:  For the year ended December 31, 2014, total operating expenses were $33.3 million compared with $35.8 million for 2013.  This decrease in 2014 resulted from the Company's initiatives to manage expenses in line with revenues. Expenses were also impacted by reduced clinical activities following the conclusion of several Caldolor® Phase IV studies.

      Total operating expenses for the three months ended December 31, 2014 were $8.4 million compared to $10.6 million the prior year period.

      Adjusted Earnings:  This performance measure represents net income attributable to common shareholders with adjustments for the impact of income taxes, depreciation, amortization, share based compensation expenses, and non-recurring expenses. A reconciliation to GAAP net income is provided in this release.

      For the year ended December 31, 2014, Adjusted Earnings were $6.3 million, or $0.35 per diluted share compared to a loss of $(1.8) million in 2013, a loss of $(0.10) per diluted share. 

      For the three months ended December 31, 2014, Adjusted Earnings were $1.8 million or $0.10 per diluted share compared to a loss of $(1.9) million or $(0.10) per diluted share for the prior year period.

      Balance Sheet:  As of December 31, 2014, cash and marketable securities were $55 million, similar to the end of the prior year. Total assets at December 31, 2014, were $95.4 million up from $87.6 million at the end of 2013.

      As of December 31, 2014, the Company had no borrowing outstanding on its line of credit and over $44 million of tax loss carry forwards resulting from the prior exercise of stock options. The Company had approximately 17.1 million common shares issued and outstanding, compared to approximately 18 million shares at the end of the prior year.

      Conference Call and Webcast

      A conference call and live Internet webcast will be held on Tuesday, March 3, 2015 at 4:30 p.m. Eastern Time to discuss the Company's fourth quarter and annual 2014 financial results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 79652184. The live webcast and rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.

      About Cumberland Pharmaceuticals

      Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's five marketed products include Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, for treatment of pain and fever, Kristalose® (lactulose) for Oral Solution, a prescription laxative, Vaprisol® (conivaptan) Injection, for the treatment of hyponatremia and Omeclamox-Pak® for the treatment of H. pylori and duodenal ulcer disease. Cumberland is developing Hepatoren® (ifetroban) Injection for the treatment of Hepatorenal Syndrome and Boxaban® (ifetroban) Oral Capsule for treatment of aspirin-exacerbated respiratory disease. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the Company's website www.cumberlandpharma.com.

      About Acetadote® (acetylcysteine) Injection

      Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma or where there is a history of bronchospasm. The total volume administered should be adjusted for patients weighing less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted, fluid overload can occur, potentially resulting in hyponatremia, seizure and death.  For full prescribing information, visit www.acetadote.com.

      About Caldolor® (ibuprofen) Injection

      Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticarial, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor.  For full prescribing information, including boxed warning, visit www.caldolor.com.

      About Kristalose® (lactulose) Oral Solution

      Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient.  Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing information, visit www.kristalose.com.

      About Omeclamox®-Pak (omeprazole, clarithromycin, amoxicillin)

      Omeprazole is an antisecretory drug, which works by decreasing the amount of acid the stomach produces. Clarithromycin and amoxicillin are antibacterial drugs, which inhibit the growth of bacteria allowing the stomach lining to heal. Omeclamox-Pak is contraindicated in patients with a history of hypersensitivity to omeprazole, any macrolide antibiotic or penicillin. The safety and effectiveness of Omeclamox-Pak in the pediatric population has not yet been established. Omeclamox-Pak was approved by the U.S. Food and Drug Administration in 2011. For full prescribing information, visit www.omeclamox.com.

      About Vaprisol® (conivaptan hydrochloride) Injection

      Vaprisol an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal.  This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia.  The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion. Vaprisol was approved by the U.S. Food and Drug Administration in 2005 for euvolemic hyponatremia and in 2007 for hypervolemic hyponatremia. For full prescribing information, visit www.vaprisol.com.

      Forward-Looking Statements

      This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's most recent Form 10-K and subsequent 10-Q's as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.

      CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
      Consolidated Balance Sheets
      (unaudited)
      December 31, 2014 and 2013










      2014



      2013









      ASSETS







      Current assets:







      Cash and cash equivalents


      $

      39,866,037



      $

      40,869,457


      Marketable securities


      14,841,418



      14,019,761


      Accounts receivable, net of allowances


      5,504,728



      4,530,424


      Inventories


      5,600,319



      5,722,882


      Prepaid and other current assets


      1,351,324



      825,675


      Deferred tax assets


      3,651,145



      2,711,516


      Total current assets


      70,814,971



      68,679,715


      Property and equipment, net


      651,030



      880,647


      Intangible assets, net


      21,568,541



      15,498,819


      Deferred tax assets


      578,592



      1,208,891


      Other assets


      1,791,980



      1,345,666


      Total assets


      $

      95,405,114



      $

      87,613,738









      LIABILITIES AND EQUITY







      Current liabilities:







      Accounts payable


      $

      3,242,713



      $

      2,035,853


      Other current liabilities


      10,506,769



      5,509,917


      Total current liabilities


      13,749,482



      7,545,770


      Revolving line of credit


      —



      —


      Other long-term liabilities


      902,841



      776,125


      Total liabilities


      14,652,323



      8,321,895


      Commitments and contingencies







      Equity:







      Shareholders' equity:







      Common stock – no par value; 100,000,000 shares authorized; 17,118,993 and 17,985,503 shares issued and outstanding as of December 31, 2014 and 2013, respectively


      61,942,410



      63,073,941


      Retained earnings


      18,818,263



      16,394,540


      Total shareholders' equity


      80,760,673



      79,468,481


      Noncontrolling interests


      (7,882)



      (176,638)


      Total equity


      80,752,791



      79,291,843


      Total liabilities and equity


      $

      95,405,114



      $

      87,613,738


      CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
      Consolidated Statements of Operations and Comprehensive Income (Loss)
      (Unaudited)








      Three months ended

      December 31,


      Years ended

      December 31,



      2014



      2013



      2014



      2013















      Revenues:













      Net product revenue


      $

      9,293,954



      $

      8,054,928



      $

      36,683,762



      $

      31,100,698


      Other revenue


      35,458



      104,739



      218,109



      926,764


      Net revenues


      9,329,412



      8,159,667



      36,901,871



      32,027,462


      Costs and expenses:













      Cost of products sold


      1,360,909



      2,145,011



      5,053,165



      5,439,422


      Selling and marketing


      3,536,236



      3,761,552



      14,902,202



      14,387,745


      Research and development


      767,109



      1,339,295



      3,389,419



      5,615,501


      General and administrative


      2,206,037



      3,100,407



      8,401,560



      9,489,976


      Amortization


      512,983



      285,479



      1,596,689



      896,156


      Total costs and expenses


      8,383,274



      10,631,744



      33,343,035



      35,828,800


      Operating income (loss)


      946,138



      (2,472,077)



      3,558,836



      (3,801,338)


      Interest income


      46,555



      68,582



      251,447



      230,291


      Interest expense


      (15,716)



      (40,701)



      (67,074)



      (103,422)


      Income (loss) before income taxes


      976,977



      (2,444,196)



      3,743,209



      (3,674,469)


      Income tax (expense) benefit


      (328,414)



      932,801



      (1,380,744)



      1,523,051


      Net income (loss)


      648,563



      (1,511,395)



      2,362,465



      (2,151,418)


      Net loss at subsidiary attributable to noncontrolling interests


      20,350



      11,032



      61,258



      46,804


      Net income (loss) attributable to common shareholders


      $

      668,913



      $

      (1,500,363)



      $

      2,423,723



      $

      (2,104,614)















      Earnings (loss) per share attributable to common shareholders:













      Basic


      $

      0.04



      $

      (0.08)



      $

      0.14



      $

      (0.11)


      Diluted


      $

      0.04



      $

      (0.08)



      $

      0.14



      $

      (0.11)


      Weighted-average common shares outstanding:













      Basic


      17,281,502



      18,072,805



      17,617,765



      18,332,997


      Diluted


      17,629,434



      18,072,805



      17,899,632



      18,332,997















      Comprehensive income (loss) attributable to common shareholders


      668,913



      (1,500,363)



      2,423,723



      (2,104,614)


      Net loss at subsidiary attributable to noncontrolling interests


      20,350



      11,032



      61,258



      46,804


      Total comprehensive income (loss)


      $

      648,563



      $

      (1,511,395)



      $

      2,362,465



      $

      (2,151,418)
















      CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
      Condensed Consolidated Statements of Cash Flows
      (Unaudited)
      Years ended December 31, 2014 and 2013











      2014



      2013











      Cash flows from operating activities:








      Net income (loss)


      $

      2,362,465



      $

      (2,151,418)



      Adjustments to reconcile net income (loss) to net cash flows provided by operating activities:








      Depreciation and amortization expense


      1,989,564



      1,301,835



      Deferred tax benefit


      (309,330)



      (1,579,918)



      Share-based compensation


      761,663



      674,955



      Excess tax benefit derived from exercise of stock options


      (1,653,028)



      (48,024)



      Noncash interest expense


      38,634



      24,075



      Noncash investment (gains) losses


      (52,040)



      178,822



      Net changes in assets and liabilities affecting operating activities, net of effect of business combination:








      Accounts receivable


      (974,304)



      1,486,777



      Inventories


      1,532,563



      495,473



      Prepaid, other current assets and other assets


      (1,011,365)



      117,021



      Accounts payable and other accrued liabilities


      3,846,482



      58,855



      Other long-term liabilities


      162,127



      187,673



      Net cash provided by operating activities


      6,693,431



      746,126



      Cash flows from investing activities:








      Additions to property and equipment


      (163,258)



      (97,412)



      Cash paid for acquisitions


      (2,000,000)



      —



      Additions to intangible assets


      (3,101,565)



      (7,462,080)



      Proceeds from sale of marketable securities


      3,437,645



      6,859,061



      Purchases of marketable securities


      (4,207,262)



      (4,371,508)



      Net cash used in investing activities


      (6,034,440)



      (5,071,939)



      Cash flows from financing activities:








      Net repayments on line of credit


      —



      (4,359,951)



      Repurchase of common shares


      (4,315,444)



      (4,800,908)



      Sale of subsidiary shares to noncontrolling interest


      1,000,005



      —



      Exercise of stock options


      —



      (41,276)



      Excess tax benefit derived from exercise of stock options


      1,653,028



      48,024



      Net cash used in financing activities


      (1,662,411)



      (9,154,111)



      Net decrease in cash and cash equivalents


      (1,003,420)



      (13,479,924)



      Cash and cash equivalents, beginning of year


      40,869,457



      54,349,381



      Cash and cash equivalents, end of year


      $

      39,866,037



      $

      40,869,457



      CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
      Reconciliation of Net Income (Loss) Attributable to Common Shareholders to Adjusted Earnings and Adjusted Diluted Earnings Per Share
      (Unaudited)








      Three months ended

      December 31,


      Three months ended

      December 31,



      2014



      2014



      2013




      2013


















      Earnings impact


      Earnings per share impact


      Earnings impact



      Earnings per share impact

      Net income (loss) attributable to common shareholders


      $

      668,913



      $

      0.04



      $

      (1,500,363)




      $

      (0.08)


      Less: Net loss at subsidiary attributable to noncontrolling interests


      20,350



      —



      11,032




      —


      Net income (loss)


      648,563



      0.04



      (1,511,395)




      (0.08)


      Adjustments to net income (loss)












      —


      Income tax expense (benefit)


      328,414



      0.02



      (932,801)




      (0.05)


      Depreciation and amortization expense


      605,953



      0.03



      384,823




      0.02


      Share-based compensation expense


      219,545



      0.01



      194,149




      0.01


      Interest income


      (46,555)



      —



      (68,582)




      —


      Interest expense


      15,716



      —



      40,701




      —


      Adjusted Earnings and Adjusted Diluted Earnings Per Share


      $

      1,771,636



      $

      0.10



      $

      (1,893,105)




      $

      (0.10)
















      Diluted weighted-average common shares outstanding:





      17,629,434







      18,072,805


















      Twelve months ended

      December 31,


      Twelve months ended

      December 31,



      2014



      2014



      2013



      2013

















      Earnings

      impact


      Earnings per share impact


      Earnings

      impact


      Earnings per share impact

      Net income (loss) attributable to common shareholders


      $

      2,423,723



      $

      0.14



      $

      (2,104,614)



      $

      (0.11)


      Less: Net loss at subsidiary attributable to noncontrolling interests


      61,258



      —



      46,804



      —


      Net income (loss)


      2,362,465



      0.13



      (2,151,418)



      (0.12)


      Adjustments to net income (loss)













      Income tax expense (benefit)


      1,380,744



      0.08



      (1,523,051)



      (0.08)


      Depreciation and amortization expense


      1,989,564



      0.11



      1,301,835



      0.07


      Share-based compensation expense


      761,663



      0.04



      674,955



      0.04


      Interest income


      (251,447)



      (0.01)



      (230,291)



      (0.01)


      Interest expense


      67,074



      —



      103,422



      0.01


      Adjusted Earnings and Adjusted Diluted Earnings Per Share


      $

      6,310,063



      $

      0.35



      $

      (1,824,548)



      $

      (0.10)















      Diluted weighted-average common shares outstanding:





      17,899,632






      18,332,997



      The Company provided the above adjusted supplemental financial performance measures, which are considered "non-GAAP" financial measures under applicable Securities and Exchange Commission rules and regulations. These financial measures should be considered supplemental to and not as a substitute for financial information prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). The definition of these supplemental measures may differ from similarly titled measures used by others.

      Because these supplemental financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the supplemental financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.

      Cumberland's management believes these supplemental financial performance measures are important as they are used by management, along with financial measures in accordance with GAAP, to evaluate the Company's operating performance.  In addition, Cumberland believes that they will be used by certain investors to measure the Company's operating results. Management believes that presenting these supplemental measures provides useful information about the Company's underlying performance across reporting periods on a consistent basis by excluding items that Cumberland does not believe are indicative of its core business performance or reflect long-term strategic activities.  These items are not settled through cash payments and include: depreciation, amortization, share-based compensation expense and income taxes.  Cumberland utilizes its net operating loss carryforwards to pay minimal income taxes.  In addition, the use of these financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company's operating performance.

      The Company defines these supplemental financial measures as follows:

      • Adjusted Earnings: net income attributable to common shareholders adjusted for the impact of income taxes, depreciation and amortization expense, share-based compensation expense and interest income and expense.
      • Adjusted Diluted Earnings Per Share: Adjusted Earnings divided by diluted weighted-average common shares outstanding.

      Logo - http://photos.prnewswire.com/prnh/20140505/84325

      SOURCE Cumberland Pharmaceuticals Inc.

      Modal title

      Also from this source

      CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE

      Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced...

      CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q3 2026 FINANCIAL RESULTS

      Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare...

      More Releases From This Source

      Explore

      Pharmaceuticals

      Pharmaceuticals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.